Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.
You may also be interested in...
Alnylam CEO John Maraganore: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
In part two of this interview, the Alnylam chief executive discusses the thought process behind the biotech’s cutback in staff this past January and its $87 million cash raise in February.
Alnylam CEO John Maraganore – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.
Alnylam Announces 33% Staff Cut, Will Focus Internally On Two Lead RNAi Programs
The RNA interference pioneer will focus on two candidates, ALN-TTR02 for transthyretin-mediated amyloidosis and ALN-APC for hemophilia, while seeking partners for its other “5x15” programs.